Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The triple therapy of metformin, a DPP-4 inhibitor and a SGLT-2 inhibitor has a very low treatment related hypoglycaemia risk, leads to a further, almost additive reduction of glycaemic parameters, a body weight loss in the same range as with a mono- or dual therapy with a SGLT-2 inhibitor and also to the expected SGLT-2 inhibitor induced reduction of blood pressure
While tirzepatide is best known as the active ingredient in injectable GLP-1 medications like Zepbound, its also the active ingredient in newer sublingual (under the tongue) GLP-1 medications
Some patients do regain weight after stopping GLP-1 medications, which is one reason they may consider bariatric surgery as a longer-term treatment option.
On the right bottom: GHK-Cu treated skin
